Abstract #0563

CM101: an optimized MR probe targeting type I collagen for detection of liver fibrosis

Christian T. Farrar¹, Richard Kennan², Eric Gale¹, Ian Ramsay^1,3, Ricard Masia⁴, Gunisha Arora⁵, Kailyn Looby⁵, Lan Wei⁵, Michelle Bunzel², Chunlian Zhang², Yonghua Zhu², Taro Akiyama², Michael Klimas², Shirly Pinto², Himashinie Diyabalanage³, Valerie Humblet³, Bryan C. Fuchs⁵, and Peter Caravan¹

¹Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United States, ²Merck Research Laboratories, Kenilworth, NJ, United States, ³Collagen Medical, Belmont, MA, United States, ⁴Pathology, Massachusetts General Hospital, Boston, MA, ⁵Surgical Oncology, Massachusetts General Hospital, Boston, MA, United States

Recent molecular MR approaches targeting collagen demonstrated the promise of noninvasive detection and staging of liver fibrosis and monitoring treatment response, but the molecular probe used was not suitable for clinical translation due to the low stability of the Gd chelator chosen. CM-101 is a new peptide based probe using the highly stable Gd-DOTA chelate that is rapidly eliminated from plasma intact into the urine and shows no sign of Gd accumulation. CM-101 robustly detected liver fibrosis in a bile duct ligation model in rats and in a CCl₄ mouse model.

This abstract and the presentation materials are available to members only; a login is required.

Join Here